Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYP-1901 vs Aflibercept in Diabetic Macular Edema
NCT07449923Phase 3Active, not recruiting
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of vorolanib in diabetic macular edema (DME) (2 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Best Corrected Visual Acuity at 56 weeks. Started Feb 2026; status: active, not recruiting.
02
Drugs
vorolanib
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07449923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449923.